| Synonym |
| Thai / English name |
Part Used : ไม่ระบุActivity : CYP2C19 INDUCTIONSolvent/Active Compound :Type of experiment : humanType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : No effect on CYP1A2, CYP3A4, CYP2E1 CYP2D6 activity in humans, but moderate inducer of CYP2C19.Note : Data incomplete, data from review article.
Part Used : ไม่ระบุActivity : CYP2C19 INDUCTIONSolvent/Active Compound :Type of experiment : humanType of animal : -Type of study : non specifiedN(Total) : -N(Treatment) : -Sex : -Age : -Route : Non-specifiedDose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : RitonavirDose/Conc.(drug) : -Result : PositiveRemark : Most reports unconfirmed. No effect on CYP1A2, CYP3A4, CYP2E1, CYP2D6 activity in humans, but moderate inducer of CYP2C19. Interaction reported with omeprazole in Chinese patients and fatal seizures in a patient on antieplilepsy medication. Caution if taken with warfarin, antiplatelet dugs, alprazolam, donezepil, trazodone, anticancer drugs.Note : Data from review, data incomplete.
Part Used : ใบActivity : CYP2C19 INDUCTIONSolvent/Active Compound : Ginkgo biloba leaf ext. (GBE)Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : OmeprazoleDose/Conc.(drug) : -Result : NegativeRemark : The metabolism pathways involved for GBE were identified by preincubation of cryopreserved human primary hepatocytes (HPHs) with selective inhibitors of CYP2C19 (omeprazole).Note : Result: GBE showed the inhibition of PAF-induced platelet aggregation with IC50 of 33 mg/L-1, 30% enhancement over the control. These effects of GBE were reduced significantly by selectively inhibiting CYP1A2 but CYP2B6, 2C19, 2E1 and 3A4. The inhibitive effects of GBE on PAF induced platelet aggregation are regulated by CYP1A2. Data incomplete.
Part Used : ใบActivity : CYP2C19 INDUCTIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Cross overN(Total) : 14*N(Treatment) : 7**Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : Voriconazole 200 mg after administration of Ginkgo biloba 120 mg twice daily.Duration : 12 daysType of interaction : PharmacokineticsInteraction with drug : VoriconazoleDose/Conc.(drug) : -Result : EquivocalRemark : * Healthy and nonsmoking volunteers. ** CYP2C19 extensive metabolizers (2C19*1/2C19*1). Results: For extensive metabolizers, the median value for voriconazole area under the plasma concentration time cruve from zero to infinity (AUC0-infinity) was 5.17 microgram/mL after administration of voriconazole alone and 4.28 microgram/mL after voriconazole with Ginkgo biloba (p>0.05). The other pharmacokinetic parameters of voriconazole such as AUC0-24, time to reach maximum concentration, half-life, and apparent clearance also did not change significantly for expensive metabolizers in the presence of Ginkgo biloba.Note : - 2 phase randomized crossover study with 4 weeks washout between phases. - Data incomplete.
Part Used : ใบActivity : CYP2C19 INDUCTIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Cross overN(Total) : 14*N(Treatment) : 7**Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : Voriconazole 200 mg after administration of Ginkgo biloba 120 mg twice daily.Duration : 12 daysType of interaction : PharmacokineticsInteraction with drug : VoriconazoleDose/Conc.(drug) : -Result : EquivocalRemark : * Healthy and nonsmoking volunteers. ** CYP2C19 poor metabolizers (2C19*2/2C19*2). Results: Pharmacokinetic parameters of voriconazole for poor metabolizers were similar pattern of extensive metabolizers.Note : - 2 phase randomized crossover study with 4 weeks washout between phases. - Data incomplete.
